You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProgesterone
Accession NumberDB00396  (APRD00700)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem]
Structure
Thumb
Synonyms
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
17alpha-Progesterone
17α-progesterone
4-Pregnene-3,20-dione
Agolutin
Akrolutin
Corpus Luteum Hormone
Crinone
delta(4)-Pregnene-3,20-dione
Gelbkoerperhormon
Luteohormone
Lutogynon
Pregn-4-ene-3,20-dione
Progesteron
Progesterona
Progestérone
Progesterone
Progesteronum
External Identifiers
  • BP 14
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Progesterone Injectionsolution50 mgintramuscularActavis Pharma Company2016-04-13Not applicableCanada
Crinonegel45 mg/1.125gvaginalActavis Pharma, Inc.1997-05-13Not applicableUs
Crinonegel90 mg/1.125gvaginalActavis Pharma, Inc.1997-05-13Not applicableUs
Crinonegel8 %vaginalEmd Serono A Division Of Emd Inc Canada2000-05-20Not applicableCanada
Crinonegel90 mg/1.125gvaginalColumbia Laboratories, Inc.1997-05-13Not applicableUs
Crinonegel45 mg/1.125gvaginalActavis Pharma, Inc.1997-05-13Not applicableUs
Crinonegel45 mg/1.125gvaginalColumbia Laboratories, Inc.1997-05-13Not applicableUs
Crinonegel90 mg/1.125gvaginalActavis Pharma, Inc.1997-05-13Not applicableUs
Crinonegel90 mg/1.125gvaginalColumbia Laboratories, Inc.1997-05-13Not applicableUs
Endometrininsert100 mg/1vaginalFerring Pharmaceuticals Inc.2007-06-21Not applicableUs
Endometrinvaginal tablet, effervescent100 mgvaginalFerring Inc2009-11-30Not applicableCanada
Gesterol In Oil-liq Im 50mg/mlliquid50 mgintramuscularGermiphene Corporation1995-12-311999-04-14Canada
PMS-progesterone Inj 50mg/ml USPliquid50 mgintramuscularPharmascience Inc1989-12-312004-01-21Canada
Prochievegel90 mg/1.125gvaginalColumbia Laboratories1997-05-13Not applicableUs
Prochievegel45 mg/1.125gvaginalColumbia Laboratories1997-05-13Not applicableUs
Progesteronecapsule200 mg/1oralWatson Laboratories, Inc.2010-07-30Not applicableUs
Progesteronecapsule200 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-30Not applicableUs
Progesteroneinjection, solution50 mg/mLintramuscularActavis Pharma, Inc.1978-05-11Not applicableUs
Progesteronecapsule100 mg/1oralWatson Laboratories, Inc.2010-07-30Not applicableUs
Progesterone Inj 50mg/ml USPliquid50 mgintramuscularCytex Pharmaceuticals Inc1992-12-31Not applicableCanada
Prometriumcapsule100 mgoralMerck Canada Inc1995-12-31Not applicableCanada
Prometriumcapsule100 mg/1oralAbb Vie Inc.2010-07-30Not applicableUs
Prometriumcapsule100 mg/1oralAvera Mc Kennan Hospital2015-08-11Not applicableUs
Prometriumcapsule200 mg/1oralAbb Vie Inc.2010-07-30Not applicableUs
Prometriumcapsule200 mg/1oralPhysicians Total Care, Inc.2004-11-03Not applicableUs
Prometriumcapsule200 mg/1oralbryant ranch prepack2010-07-30Not applicableUs
Prometriumcapsule100 mg/1oralPhysicians Total Care, Inc.2003-03-14Not applicableUs
Prometriumcapsule100 mg/1oralbryant ranch prepack2010-07-30Not applicableUs
Teva-progesteronecapsule100 mgoralTeva Canada Limited2015-04-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Progesteronecapsule200 mg/1oralAkorn, Inc.2012-10-04Not applicableUs
Progesteronecapsule100 mg/1oralTeva Pharmaceuticals USA Inc2012-03-01Not applicableUs
Progesteronecapsule200 mg/1oralBanner Life Sciences Llc.2015-10-01Not applicableUs
Progesteronecapsule100 mg/1oralGolden State Medical Supply, Inc.2014-04-23Not applicableUs
Progesteronecapsule100 mg/1oralBanner Pharmacaps2014-01-01Not applicableUs
Progesteronecapsule100 mg/1oralAv Kare, Inc.2013-06-042015-12-29Us
Progesteronecapsule200 mg/1oralTeva Pharmaceuticals USA Inc2012-03-01Not applicableUs
Progesteronecapsule200 mg/1oralGolden State Medical Supply, Inc.2014-04-23Not applicableUs
Progesteronecapsule200 mg/1oralBanner Pharmacaps2014-01-01Not applicableUs
Progesteronecapsule100 mg/1oralAv Kare, Inc.2014-09-29Not applicableUs
Progesteroneinjection50 mg/1intramuscularWest ward Pharmaceutical Corp2010-10-28Not applicableUs
Progesteronecapsule200 mg/1oralAv Kare, Inc.2013-06-042015-12-29Us
Progesteroneinjection, solution50 mg/mLintramuscularFresenius Kabi USA, LLC2001-07-19Not applicableUs
Progesteronecapsule100 mg/1oralAkorn, Inc.2012-10-04Not applicableUs
Progesteronecapsule200 mg/1oralAv Kare, Inc.2014-09-29Not applicableUs
Progesteroneinjection, solution50 mg/mLintramuscularAmerican Regent, Inc.2010-09-29Not applicableUs
Progesteronecapsule100 mg/1oralBanner Life Sciences Llc.2015-10-01Not applicableUs
Progesterone Injection USPinjection, solution50 mg/mLintramuscularPharma Force, Inc.2009-09-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AgolutinBiotika
CyclogestActavis
GesterolNot Available
GestoneNordic Pharma
ProgestasertNot Available
ProgestogelBesins
Qi NingAisheng Pharmaceutical
RelantanAversi
SustenSun Pharma
UtrogestanBesins
UtrogestranFaran Laboratories
UtrovinBestochem
VasclorVerisfield
Brand mixtures
NameLabellerIngredients
Estrogel PropakMerck Canada Inc
SaltsNot Available
Categories
UNII4G7DS2Q64Y
CAS number57-83-0
WeightAverage: 314.4617
Monoisotopic: 314.224580204
Chemical FormulaC21H30O2
InChI KeyInChIKey=RJKFOVLPORLFTN-LEKSSAKUSA-N
InChI
InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
IUPAC Name
(1S,2R,10S,11S,14S,15S)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[[email protected]](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.
PharmacodynamicsProgesterone is a naturally occuring progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Progesterone tricks the body processes into thinking that ovulation has already occurred by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.
Mechanism of actionProgesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.
Related Articles
AbsorptionProgesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours.
Volume of distributionNot Available
Protein binding96%-99%
Metabolism

Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones.

SubstrateEnzymesProduct
Progesterone
6β-HydroxyprogesteroneDetails
Progesterone
2β-HydroxyprogesteroneDetails
Progesterone
21-HydroxyprogesteroneDetails
Progesterone
17β-HydroxyprogesteroneDetails
17β-Hydroxyprogesterone
17β,21-HydroxyprogesteroneDetails
Progesterone
16β-HydroxyprogesteroneDetails
Progesterone
16β-HydroxyprogesteroneDetails
Progesterone
Not Available
15β-HydroxyprogesteroneDetails
Progesterone
Not Available
7β-HydroxyprogesteroneDetails
Route of eliminationThe glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. Progesterone metabolites are excreted mainly by the kidneys.
Half life34.8-55.13 hours
Clearance
  • 2510 +/- 135 L/day [cycling women]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
17-alpha-hydroxylase deficiency (CYP17)DiseaseSMP00566
Corticosterone methyl oxidase I deficiency (CMO I)DiseaseSMP00577
SteroidogenesisMetabolicSMP00130
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase DeficiencyDiseaseSMP00373
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAHDiseaseSMP00371
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase DeficiencyDiseaseSMP00372
11-beta-hydroxylase deficiency (CYP11B1)DiseaseSMP00575
Corticosterone methyl oxidase II deficiency - CMO IIDiseaseSMP00578
21-hydroxylase deficiency (CYP21)DiseaseSMP00576
Apparent mineralocorticoid excess syndromeDiseaseSMP00717
3-Beta-Hydroxysteroid Dehydrogenase DeficiencyDiseaseSMP00718
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.982
Caco-2 permeable+0.7724
P-glycoprotein substrateSubstrate0.5449
P-glycoprotein inhibitor IInhibitor0.8841
P-glycoprotein inhibitor IIInhibitor0.6043
Renal organic cation transporterNon-inhibitor0.6931
CYP450 2C9 substrateNon-substrate0.847
CYP450 2D6 substrateNon-substrate0.8795
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9533
CYP450 2C19 inhibitorNon-inhibitor0.6514
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8203
Ames testNon AMES toxic0.9626
CarcinogenicityNon-carcinogens0.9151
BiodegradationNot ready biodegradable0.9575
Rat acute toxicity1.8041 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7451
hERG inhibition (predictor II)Non-inhibitor0.7454
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb
  • Amarin pharmaceuticals inc
  • Solvay pharmaceuticals
  • Esi pharmacal
  • Unimed pharmaceuticals llc
  • Watson laboratories inc
  • App pharmaceuticals llc
  • Eli lilly and co
  • Pharmaforce inc
  • Alza corp
  • Ferring pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Solutionintramuscular50 mg
Gelvaginal45 mg/1.125g
Gelvaginal8 %
Gelvaginal90 mg/1.125g
Insertvaginal100 mg/1
Vaginal tablet, effervescentvaginal100 mg
Metered-dose pump; capsuleoral; transdermal
Injectionintramuscular50 mg/1
Injection, solutionintramuscular50 mg/mL
Liquidintramuscular50 mg
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral200 mg/1
Prices
Unit descriptionCostUnit
Prochieve 4% Gel (18 Applicators Per Box)160.18USD tube
Crinone 8% Gel (1 Box = 6 Applications)84.26USD box
Prochieve 8% Gel 1.45 gm Tube14.83USD tube
Crinone 8% gel13.61USD g
Prochieve 8% gel12.0USD g
Prochieve 4% gel8.56USD g
Progesterone 50 mg/ml6.6USD ml
Progesterone oil 50 mg/ml vial3.88USD ml
Prometrium 200 mg capsule3.84USD capsule
First-progesterone vgs 400 susuppositoryp3.33USD each
First-progesterone vgs 200 suppository3.15USD each
First-progesterone vgs 100 suppository3.0USD each
First-progesterone vgs 50 suppository2.93USD each
First-progesterone vgs 25 suppository2.88USD each
Prometrium 100 mg capsule1.69USD capsule
Progesterone powder micronized0.74USD g
Progesterone powder milled0.73USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5543150 No1993-09-152013-09-15Us
US7300664 No1999-11-172019-11-17Us
US7320800 No1999-11-172019-11-17Us
US7393543 No1999-11-172019-11-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point121 °CPhysProp
water solubility8.81 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.87HANSCH,C ET AL. (1995)
logS-4.43ADME Research, USCD
Caco2 permeability-4.37ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00546 mg/mLALOGPS
logP3.58ALOGPS
logP4.15ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)18.92ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity92.71 m3·mol-1ChemAxon
Polarizability37.15 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MSsplash10-0fbc-5910000000-422e38df6de7e8b0a4b7View in MoNA
GC-MSGC-MS Spectrum - GC-MSsplash10-0fbc-5910000000-385f45345742235da8e0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-014i-1009000000-0f8b7c3e6c2265c3889fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-052b-8900000000-0b0167121b798e7e7534View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-052b-9400000000-881510cbcecd9cb61f4fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (JEOL JMS-01-SG-2) , Positivesplash10-024l-6923000000-639c7405f69825de7f90View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-52) , Positivesplash10-0229-2941000000-1e075d8489b79cf4e34aView in MoNA
MSMass Spectrum (Electron Ionization)splash10-006x-7931000000-f6ad83adccd7e016fa29View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Nejib M. Nasraoui, Alain Piasco, “Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them.” U.S. Patent US5223492, issued May, 1971.

US5223492
General References
  1. Allen WM: THE ISOLATION OF CRYSTALLINE PROGESTIN. Science. 1935 Aug 2;82(2118):89-93. [PubMed:17747122 ]
  2. Allen WM: Progesterone: how did the name originate? South Med J. 1970 Oct;63(10):1151-5. [PubMed:4922128 ]
  3. Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, Gonzalez Deniselle MC, Gonzalez SL, Ibanez C, Labombarda F, Coirini H, Baulieu EE, De Nicola AF: Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res. 2004 Jun;14 Suppl A:S18-33. [PubMed:15135772 ]
  4. Hould FS, Fried GM, Fazekas AG, Tremblay S, Mersereau WA: Progesterone receptors regulate gallbladder motility. J Surg Res. 1988 Dec;45(6):505-12. [PubMed:3184927 ]
External Links
ATC CodesG03FA04G03DA04
AHFS Codes
  • 68:32.00
PDB EntriesNot Available
FDA labelDownload (86.6 KB)
MSDSDownload (74.2 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of Progesterone can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with 2-mercaptobenzothiazole.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Progesterone.
AbirateroneThe serum concentration of Progesterone can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Progesterone.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Progesterone.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Progesterone.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Progesterone.
AcetaminophenThe serum concentration of Progesterone can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Progesterone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Progesterone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Progesterone.
AfatinibThe serum concentration of Progesterone can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Progesterone.
AlbendazoleThe serum concentration of Progesterone can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Progesterone.
AlectinibThe serum concentration of Progesterone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Progesterone can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Progesterone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Progesterone.
AmantadineThe serum concentration of Progesterone can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Progesterone.
Aminohippuric acidThe serum concentration of Progesterone can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Progesterone can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Progesterone.
AmitriptylineThe serum concentration of Progesterone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Progesterone can be increased when it is combined with Amlodipine.
AmorolfineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amorolfine.
Amphotericin BThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amphotericin B.
AmprenavirThe serum concentration of Progesterone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Progesterone can be increased when it is combined with Amsacrine.
AN2690The therapeutic efficacy of Progesterone can be decreased when used in combination with AN2690.
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Progesterone.
AnidulafunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Anidulafungin.
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Progesterone.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Progesterone.
AprepitantThe serum concentration of Progesterone can be increased when it is combined with Aprepitant.
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone.
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Progesterone.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.
ArmodafinilThe metabolism of Progesterone can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Progesterone.
ArtemetherThe therapeutic efficacy of Progesterone can be decreased when used in combination with Artemether.
AstemizoleThe serum concentration of Progesterone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Progesterone.
AtazanavirThe serum concentration of Progesterone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Progesterone.
AtenololThe serum concentration of Progesterone can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Progesterone can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Progesterone can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Progesterone.
AzelastineThe serum concentration of Progesterone can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Progesterone can be increased when it is combined with Azithromycin.
Bafilomycin A1The therapeutic efficacy of Progesterone can be decreased when used in combination with Bafilomycin A1.
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Progesterone.
BenzocaineThe serum concentration of Progesterone can be increased when it is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Benzoic Acid.
BepridilThe serum concentration of Progesterone can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Progesterone.
BetaxololThe metabolism of Progesterone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Progesterone can be decreased when it is combined with Bexarotene.
BifonazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Bifonazole.
BiperidenThe serum concentration of Progesterone can be increased when it is combined with Biperiden.
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.
BoceprevirThe metabolism of Progesterone can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Progesterone.
BortezomibThe metabolism of Progesterone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Progesterone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Progesterone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Progesterone.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Progesterone.
BromocriptineThe serum concentration of Progesterone can be increased when it is combined with Bromocriptine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Progesterone.
BuprenorphineThe serum concentration of Progesterone can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Progesterone can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Progesterone can be increased when it is combined with Buspirone.
ButenafineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Butenafine.
ButoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Butoconazole.
C1 Esterase Inhibitor (Human)Progesterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Progesterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Progesterone.
CabazitaxelThe serum concentration of Progesterone can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Progesterone.
CaffeineThe serum concentration of Progesterone can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Progesterone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.
CanagliflozinThe serum concentration of Progesterone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Progesterone can be increased when it is combined with Candesartan.
CandicidinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Candicidin.
CapecitabineThe metabolism of Progesterone can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Progesterone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Progesterone can be decreased when it is combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Progesterone.
CarvedilolThe serum concentration of Progesterone can be increased when it is combined with Carvedilol.
CaspofunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Progesterone.
CelecoxibThe metabolism of Progesterone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Progesterone can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Progesterone.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Progesterone.
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Progesterone.
CeruleninThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cerulenin.
ChloramphenicolThe metabolism of Progesterone can be decreased when combined with Chloramphenicol.
ChloroquineThe serum concentration of Progesterone can be increased when it is combined with Chloroquine.
ChloroxineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Chloroxine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Progesterone.
ChlorpromazineThe serum concentration of Progesterone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Progesterone.
ChlorpropamideThe serum concentration of Progesterone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Progesterone can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Progesterone can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Progesterone can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Progesterone can be decreased when it is combined with Cholic Acid.
CiclopiroxThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ciclopirox.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Progesterone.
CilazaprilThe serum concentration of Progesterone can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Progesterone.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Progesterone.
CinacalcetThe metabolism of Progesterone can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Progesterone.
CiprofloxacinThe serum concentration of Progesterone can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Progesterone.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Progesterone.
CitalopramThe serum concentration of Progesterone can be increased when it is combined with Citalopram.
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Progesterone.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Progesterone.
ClarithromycinThe serum concentration of Progesterone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Progesterone can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Progesterone.
ClobazamThe metabolism of Progesterone can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Progesterone can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Progesterone.
ClomipramineThe serum concentration of Progesterone can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Progesterone.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Progesterone.
ClopidogrelThe metabolism of Progesterone can be decreased when combined with Clopidogrel.
ClotrimazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Progesterone.
ClozapineThe metabolism of Progesterone can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Progesterone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Progesterone.
CocaineThe metabolism of Progesterone can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Progesterone.
ColchicineThe serum concentration of Progesterone can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Progesterone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Progesterone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Progesterone.
CrizotinibThe metabolism of Progesterone can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Progesterone.
CyclophosphamideThe serum concentration of Progesterone can be increased when it is combined with Cyclophosphamide.
CyclosporineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Progesterone.
Cyproterone acetateThe serum concentration of Progesterone can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone.
DabrafenibThe serum concentration of Progesterone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Progesterone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Progesterone.
DactinomycinThe serum concentration of Progesterone can be increased when it is combined with Dactinomycin.
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone.
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Progesterone.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Progesterone.
DarifenacinThe metabolism of Progesterone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Progesterone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Progesterone can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Progesterone.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Progesterone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Progesterone.
Decanoic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Decanoic Acid.
DeferasiroxThe serum concentration of Progesterone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Progesterone can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Progesterone can be increased when it is combined with Desipramine.
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Progesterone.
DesloratadineThe serum concentration of Progesterone can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Progesterone can be decreased when it is combined with Dexamethasone.
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Progesterone.
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Progesterone.
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Progesterone.
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Progesterone.
DextromethorphanThe serum concentration of Progesterone can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Progesterone.
DiclofenacThe serum concentration of Progesterone can be increased when it is combined with Diclofenac.
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Progesterone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Progesterone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Progesterone.
DigoxinThe serum concentration of Progesterone can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Progesterone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Progesterone.
DiltiazemThe metabolism of Progesterone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Progesterone.
DiphenhydramineThe metabolism of Progesterone can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Progesterone.
DipyridamoleThe serum concentration of Progesterone can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Progesterone.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Progesterone.
DoxazosinThe serum concentration of Progesterone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Progesterone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Progesterone.
DoxycyclineThe metabolism of Progesterone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Progesterone can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Progesterone can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Progesterone.
DuloxetineThe metabolism of Progesterone can be decreased when combined with Duloxetine.
EconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Econazole.
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Progesterone.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Progesterone.
EfavirenzThe serum concentration of Progesterone can be decreased when it is combined with Efavirenz.
EfinaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Efinaconazole.
ElbasvirThe serum concentration of Progesterone can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Progesterone.
EliglustatThe metabolism of Progesterone can be decreased when combined with Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.
EnalaprilThe serum concentration of Progesterone can be increased when it is combined with Enalapril.
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Progesterone.
EnzalutamideThe serum concentration of Progesterone can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Progesterone.
ErgonovineThe serum concentration of Progesterone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Progesterone can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Progesterone.
ErythromycinThe metabolism of Progesterone can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Progesterone.
Eslicarbazepine acetateThe serum concentration of Progesterone can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Progesterone can be decreased when combined with Esomeprazole.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Progesterone.
EstramustineThe serum concentration of Progesterone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Progesterone.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Progesterone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Progesterone.
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Progesterone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Progesterone.
EtoposideThe serum concentration of Progesterone can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Progesterone can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Progesterone.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Progesterone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Progesterone.
FelodipineThe serum concentration of Progesterone can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Progesterone can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Progesterone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Progesterone.
FexofenadineThe serum concentration of Progesterone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Progesterone.
FidaxomicinThe serum concentration of Progesterone can be increased when it is combined with Fidaxomicin.
FloxuridineThe metabolism of Progesterone can be decreased when combined with Floxuridine.
FluconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Fluconazole.
FlucytosineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Flucytosine.
FluorouracilThe metabolism of Progesterone can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Progesterone can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Progesterone can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Progesterone can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Progesterone can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Progesterone.
FluvastatinThe metabolism of Progesterone can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Progesterone can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Progesterone.
FosamprenavirThe metabolism of Progesterone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Progesterone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Progesterone can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Progesterone can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Progesterone.
GefitinibThe serum concentration of Progesterone can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Progesterone.
GemfibrozilThe metabolism of Progesterone can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Progesterone can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Progesterone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Progesterone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Progesterone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Progesterone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Progesterone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Progesterone.
GlyburideThe serum concentration of Progesterone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Progesterone can be increased when it is combined with Glycerol.
GlyphosateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Glyphosate.
Gramicidin DThe serum concentration of Progesterone can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Progesterone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Progesterone.
GrepafloxacinThe serum concentration of Progesterone can be increased when it is combined with Grepafloxacin.
GriseofulvinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Griseofulvin.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Progesterone.
HaloperidolThe serum concentration of Progesterone can be increased when it is combined with Haloperidol.
HaloproginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Haloprogin.
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Progesterone.
HexetidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Hexetidine.
HirulogThe therapeutic efficacy of Hirulog can be decreased when used in combination with Progesterone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Progesterone.
HydrocortisoneThe serum concentration of Progesterone can be increased when it is combined with Hydrocortisone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Progesterone.
IdelalisibThe serum concentration of Progesterone can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Progesterone.
ImatinibThe metabolism of Progesterone can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Progesterone.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Progesterone.
ImipramineThe serum concentration of Progesterone can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Progesterone.
IndinavirThe serum concentration of Progesterone can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Progesterone.
IndomethacinThe serum concentration of Progesterone can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Progesterone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Progesterone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Progesterone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Progesterone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Progesterone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Progesterone.
IrbesartanThe metabolism of Progesterone can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Progesterone.
IsavuconazoniumThe metabolism of Progesterone can be decreased when combined with Isavuconazonium.
IsoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Isoconazole.
IsoniazidThe metabolism of Progesterone can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Progesterone can be decreased when combined with Isradipine.
ItraconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Itraconazole.
IvacaftorThe serum concentration of Progesterone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Progesterone.
IvermectinThe serum concentration of Progesterone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Progesterone can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Progesterone.
KetoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Progesterone.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Progesterone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Progesterone.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Progesterone.
LansoprazoleThe serum concentration of Progesterone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Progesterone can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Progesterone.
LeflunomideThe metabolism of Progesterone can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Progesterone.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Progesterone.
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Progesterone.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Progesterone.
LevofloxacinThe serum concentration of Progesterone can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Progesterone.
LevothyroxineThe serum concentration of Progesterone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Progesterone can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Progesterone.
LiothyronineThe serum concentration of Progesterone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Progesterone can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Progesterone.
LisinoprilThe serum concentration of Progesterone can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Progesterone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Progesterone.
LoperamideThe serum concentration of Progesterone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Progesterone can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Progesterone can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Progesterone can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Progesterone.
LosartanThe serum concentration of Progesterone can be increased when it is combined with Losartan.
LovastatinThe metabolism of Progesterone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Progesterone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Progesterone can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Progesterone can be decreased when combined with Lumefantrine.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Progesterone.
MaprotilineThe serum concentration of Progesterone can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Progesterone can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Progesterone can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Progesterone can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Progesterone can be increased when it is combined with Meprobamate.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.
MethadoneThe serum concentration of Progesterone can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Progesterone.
MethotrimeprazineThe metabolism of Progesterone can be decreased when combined with Methotrimeprazine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Progesterone.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Progesterone.
MetoprololThe serum concentration of Progesterone can be increased when it is combined with Metoprolol.
MevastatinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Mevastatin.
MexiletineThe metabolism of Progesterone can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Progesterone can be increased when it is combined with Mibefradil.
MicafunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Micafungin.
MiconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Progesterone.
MifepristoneThe metabolism of Progesterone can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Progesterone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Progesterone.
MiltefosineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miltefosine.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Progesterone.
MirabegronThe metabolism of Progesterone can be decreased when combined with Mirabegron.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Progesterone.
MitomycinThe serum concentration of Progesterone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Progesterone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Progesterone.
MoclobemideThe metabolism of Progesterone can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Progesterone can be decreased when it is combined with Modafinil.
MonensinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Monensin.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Progesterone.
MorphineThe serum concentration of Progesterone can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Progesterone.
MyxothiazolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Myxothiazol.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Progesterone.
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Progesterone.
NafcillinThe serum concentration of Progesterone can be decreased when it is combined with Nafcillin.
NaftifineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Progesterone.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Progesterone.
NaltrexoneThe serum concentration of Progesterone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Progesterone can be increased when it is combined with Naringenin.
NatamycinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Natamycin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Progesterone.
NefazodoneThe serum concentration of Progesterone can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Progesterone can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Progesterone can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Progesterone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Progesterone can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Progesterone.
NicardipineThe serum concentration of Progesterone can be increased when it is combined with Nicardipine.
NicotineThe metabolism of Progesterone can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Progesterone can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Progesterone can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Progesterone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Progesterone.
NisoldipineThe serum concentration of Progesterone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Progesterone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Progesterone can be increased when it is combined with Nitrendipine.
NitroxolineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nitroxoline.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Progesterone.
NorethisteroneThe serum concentration of Progesterone can be decreased when it is combined with Norethisterone.
NystatinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nystatin.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Progesterone.
OlaparibThe metabolism of Progesterone can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Progesterone.
OmeprazoleThe serum concentration of Progesterone can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Progesterone can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Progesterone.
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Progesterone.
OxiconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Oxiconazole.
P-NitrophenolThe serum concentration of Progesterone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Progesterone.
PaclitaxelThe serum concentration of Progesterone can be increased when it is combined with Paclitaxel.
pafuramidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with pafuramidine.
PalbociclibThe serum concentration of Progesterone can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Progesterone can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Progesterone.
PanobinostatThe metabolism of Progesterone can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Progesterone can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Progesterone can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Progesterone.
Peginterferon alfa-2bThe serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Pentamidine.
PentobarbitalThe metabolism of Progesterone can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Progesterone.
PerindoprilThe serum concentration of Progesterone can be increased when it is combined with Perindopril.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Progesterone.
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Progesterone.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Progesterone.
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Progesterone.
PhenytoinThe metabolism of Progesterone can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Progesterone.
PimozideThe serum concentration of Progesterone can be increased when it is combined with Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Progesterone.
PioglitazoneThe metabolism of Progesterone can be decreased when combined with Pioglitazone.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Progesterone.
Platelet Activating FactorThe serum concentration of Progesterone can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Progesterone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Progesterone.
PonatinibThe serum concentration of Progesterone can be increased when it is combined with Ponatinib.
PosaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Progesterone.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Progesterone.
PravastatinThe serum concentration of Progesterone can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Progesterone.
PrazosinThe serum concentration of Progesterone can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Progesterone.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Progesterone.
PrednisoneThe serum concentration of Progesterone can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Progesterone can be increased when combined with Primidone.
ProbenecidThe serum concentration of Progesterone can be increased when it is combined with Probenecid.
PromazineThe metabolism of Progesterone can be decreased when combined with Promazine.
PromethazineThe serum concentration of Progesterone can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Progesterone can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Progesterone.
PropranololThe serum concentration of Progesterone can be increased when it is combined with Propranolol.
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Progesterone.
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Progesterone.
ProtriptylineThe serum concentration of Progesterone can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Progesterone.
PyrimethamineThe metabolism of Progesterone can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Progesterone can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Progesterone.
QuinacrineThe serum concentration of Progesterone can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Progesterone.
QuinidineThe serum concentration of Progesterone can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Progesterone.
QuinineThe serum concentration of Progesterone can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Progesterone can be decreased when combined with Rabeprazole.
RadicicolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Radicicol.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Progesterone.
RanitidineThe serum concentration of Progesterone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Progesterone.
ReboxetineThe serum concentration of Progesterone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Progesterone can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Progesterone.
ReserpineThe serum concentration of Progesterone can be decreased when it is combined with Reserpine.
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Progesterone.
RifabutinThe metabolism of Progesterone can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Progesterone can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Progesterone can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Progesterone.
RilpivirineThe serum concentration of Progesterone can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Progesterone.
RitonavirThe serum concentration of Progesterone can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Progesterone.
RolapitantThe serum concentration of Progesterone can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Progesterone.
RopiniroleThe metabolism of Progesterone can be decreased when combined with Ropinirole.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Progesterone.
RosiglitazoneThe metabolism of Progesterone can be decreased when combined with Rosiglitazone.
Salicylhydroxamic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylhydroxamic Acid.
Salicylic acidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylic acid.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Progesterone.
SaquinavirThe serum concentration of Progesterone can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Progesterone.
ScopolamineThe serum concentration of Progesterone can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Progesterone can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Progesterone can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Progesterone.
SertaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sertaconazole.
SertralineThe serum concentration of Progesterone can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Progesterone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Progesterone.
SiltuximabThe serum concentration of Progesterone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Progesterone can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Progesterone.
SimvastatinThe serum concentration of Progesterone can be increased when it is combined with Simvastatin.
SinefunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sinefungin.
SirolimusThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Progesterone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Progesterone.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Progesterone.
SorafenibThe serum concentration of Progesterone can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Progesterone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Progesterone.
SpironolactoneThe serum concentration of Progesterone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Progesterone can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Progesterone can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Progesterone can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Progesterone can be decreased when it is combined with Streptozocin.
SulconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sulconazole.
SulfadiazineThe metabolism of Progesterone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Progesterone can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Progesterone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Progesterone can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Progesterone.
SumatriptanThe serum concentration of Progesterone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Progesterone can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Progesterone can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Progesterone.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Progesterone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Progesterone.
Taurocholic AcidThe serum concentration of Progesterone can be increased when it is combined with Taurocholic Acid.
TavaboroleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tavaborole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Progesterone.
TelaprevirThe metabolism of Progesterone can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Progesterone.
TelithromycinThe metabolism of Progesterone can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Progesterone can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Progesterone.
TemsirolimusThe serum concentration of Progesterone can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Progesterone can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Progesterone can be increased when it is combined with Terazosin.
TerbinafineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terbinafine.
TerconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terconazole.
TerfenadineThe serum concentration of Progesterone can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Progesterone can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Progesterone can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Progesterone can be increased when it is combined with Testosterone.
TheophyllineThe metabolism of Progesterone can be decreased when combined with Theophylline.
ThioridazineThe metabolism of Progesterone can be decreased when combined with Thioridazine.
ThymolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Thymol.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Progesterone.
TicagrelorThe serum concentration of Progesterone can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Progesterone can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Progesterone.
TioconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tioconazole.
TipranavirThe metabolism of Progesterone can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Progesterone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Progesterone.
TolbutamideThe metabolism of Progesterone can be decreased when combined with Tolbutamide.
TolnaftateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tolnaftate.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Progesterone.
TolvaptanThe serum concentration of Progesterone can be increased when it is combined with Tolvaptan.
TopiramateThe metabolism of Progesterone can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Progesterone.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Progesterone.
TranylcypromineThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Progesterone.
TrazodoneThe serum concentration of Progesterone can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Progesterone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Progesterone can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Progesterone can be decreased when it is combined with Trimethoprim.
TrimetrexateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Trimetrexate.
TrimipramineThe serum concentration of Progesterone can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Progesterone.
TroleandomycinThe serum concentration of Progesterone can be increased when it is combined with Troleandomycin.
UlipristalThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ulipristal.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Progesterone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Progesterone.
Valproic AcidThe metabolism of Progesterone can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Progesterone can be decreased when combined with Valsartan.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Progesterone.
VemurafenibThe serum concentration of Progesterone can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Progesterone can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Progesterone.
VerapamilThe metabolism of Progesterone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Progesterone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Progesterone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Progesterone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Progesterone.
VincristineThe serum concentration of Progesterone can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Progesterone can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Progesterone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Progesterone.
VoriconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Voriconazole.
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Progesterone.
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Progesterone.
ZafirlukastThe metabolism of Progesterone can be decreased when combined with Zafirlukast.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Progesterone.
ZimelidineThe serum concentration of Progesterone can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Progesterone can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take at the same time everyday.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. [PubMed:17013809 ]
  2. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. [PubMed:17015480 ]
  3. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. [PubMed:17109827 ]
  4. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. [PubMed:17138644 ]
  5. Tranguch S, Smith DF, Dey SK: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online. 2006 Nov;13(5):651-60. [PubMed:17169175 ]
  6. Luconi M, Bonaccorsi L, Maggi M, Pecchioli P, Krausz C, Forti G, Baldi E: Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane. J Clin Endocrinol Metab. 1998 Mar;83(3):877-85. [PubMed:9506743 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. [PubMed:17103262 ]
  2. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9. [PubMed:17118173 ]
  3. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. [PubMed:17203775 ]
  4. Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22. [PubMed:17341305 ]
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. [PubMed:17415709 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Rupprecht R, Reul JM, van Steensel B, Spengler D, Soder M, Berning B, Holsboer F, Damm K: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54. [PubMed:8282004 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Haidar S, Hartmann RW: C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluation. Arch Pharm (Weinheim). 2002;335(11-12):526-34. [PubMed:12596217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
activator
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Dawson-Basoa ME, Gintzler AR: Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain. 1996 Jan;64(1):169-77. [PubMed:8867260 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  3. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143 ]
  4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010 ]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  6. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  7. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  8. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  9. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. [PubMed:10329417 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:14